Christopher Gibson - Feb 22, 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Executive Officer, Director
Signature
/s/ Nathan Hatfield, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Feb 22, 2022
Transactions value $
-$1,021,540
Form type
4
Date filed
2/24/2022, 06:24 PM
Previous filing
Feb 8, 2022
Next filing
Mar 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Conversion of derivative security $0 +100K +42.73% $0.00 334K Feb 22, 2022 Direct F1, F2
transaction RXRX Class A Common Stock Sale -$1.02M -100K -29.94% $10.22 234K Feb 22, 2022 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Class B Common Stock Conversion of derivative security $0 -100K -1.29% $0.00 7.66M Feb 22, 2022 Class A Common Stock 7.66M $0.00 Direct F1, F2
holding RXRX Stock Option (Right to Buy) 416K Feb 22, 2022 Class A Common Stock 416K $11.40 Direct F5
holding RXRX Stock Option (Right to Buy) 5.44K Feb 22, 2022 Class A Common Stock 5.44K $11.40 Direct
holding RXRX Stock Option (Right to Buy) 1.47M Feb 22, 2022 Class A Common Stock 1.47M $2.47 Direct F6
holding RXRX Class B Common Stock 550K Feb 22, 2022 Class A Common Stock 550K $0.00 by LAHWRAN-3 LLC F2, F7
holding RXRX Class B Common Stock 550K Feb 22, 2022 Class A Common Stock 550K $0.00 by LAHWRAN-4 LLC F2, F8
holding RXRX Class B Common Stock 147K Feb 22, 2022 Class A Common Stock 147K $0.00 by Gibson Family Trust F2, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the conversion of Class B Common Stock into Class A Common Stock.
F2 Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F3 Shares were sold by a lender to the Reporting Person to satisfy a margin call related to a loan in which the shares served as collateral.
F4 This transaction was executed in multiple trades at prices ranging from $9.91 to $10.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F6 The option, originally for 1,500,000 shares, of which 28,646 shares have been exercised, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F7 The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F8 The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F9 The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.